Phase 2 BI 1291583: CatC Inhibitor Indication: Non-cystic fibrosis bronchiectasis This compound is under investigation, further information will be available soon. Fast Track Designation granted by the U.S. Food and Drug Administration Partnering inquiries Join our team Additional links Innovation in Immunology Respiratory Research Lung Diseases Partnering in Respiratory Diseases
